Genetic sequence variants in vitamin D metabolism pathway genes, serum vitamin D level and outcome in head and neck cancer patients

2012 ◽  
Vol 132 (11) ◽  
pp. 2520-2527 ◽  
Author(s):  
Abul Kalam Azad ◽  
Isabelle Bairati ◽  
Xin Qiu ◽  
Huayi Huang ◽  
Dangxiao Cheng ◽  
...  
Keyword(s):  
Vitamin D ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Serum Vitamin ◽  
Sequence Variants ◽  
Vitamin D Metabolism ◽  
Genetic Sequence ◽  
Serum Vitamin D ◽  
Metabolism Pathway

scholarly journals Assessment of Vitamin D Metabolism in Patients with Cushing’s Disease in Response to 150,000 IU Cholecalciferol Treatment

Nutrients ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 4329
Author(s):  
Alexandra Povaliaeva ◽  
Viktor Bogdanov ◽  
Ekaterina Pigarova ◽  
Artem Zhukov ◽  
Larisa Dzeranova ◽  
...  
Keyword(s):  
Vitamin D ◽  
Cushing’S Disease ◽  
Serum Vitamin ◽  
Urinary Free Cortisol ◽  
Cushing's Disease ◽  
Control Group ◽  
Vitamin D Metabolites ◽  
Vitamin D Metabolism ◽  
Serum Vitamin D ◽  
Free Cortisol

In this study we aimed to assess vitamin D metabolism in patients with Cushing’s disease (CD) compared to healthy individuals in the setting of bolus cholecalciferol treatment. The study group included 30 adults with active CD and the control group included 30 apparently healthy adults with similar age, sex and BMI. All participants received a single dose (150,000 IU) of cholecalciferol aqueous solution orally. Laboratory assessments including serum vitamin D metabolites (25(OH)D3, 25(OH)D2, 1,25(OH)2D3, 3-epi-25(OH)D3 and 24,25(OH)2D3), free 25(OH)D, vitamin D-binding protein (DBP) and parathyroid hormone (PTH) as well as serum and urine biochemical parameters were performed before the intake and on Days 1, 3 and 7 after the administration. All data were analyzed with non-parametric statistics. Patients with CD had similar to healthy controls 25(OH)D3 levels (p > 0.05) and higher 25(OH)D3/24,25(OH)2D3 ratios (p < 0.05) throughout the study. They also had lower baseline free 25(OH)D levels (p < 0.05) despite similar DBP levels (p > 0.05) and lower albumin levels (p < 0.05); 24-h urinary free cortisol showed significant correlation with baseline 25(OH)D3/24,25(OH)2D3 ratio (r = 0.36, p < 0.05). The increase in 25(OH)D3 after cholecalciferol intake was similar in obese and non-obese states and lacked correlation with BMI (p > 0.05) among patients with CD, as opposed to the control group. Overall, patients with CD have a consistently lower 25(OH)D3/24,25(OH)2D3 ratio, which is indicative of a decrease in 24-hydroxylase activity. This altered activity of the principal vitamin D catabolism might influence the effectiveness of cholecalciferol treatment. The observed difference in baseline free 25(OH)D levels is not entirely clear and requires further study.

scholarly journals Vitamin D deficiency in head and neck cancer patients – prevalence, prognostic value and impact on immune function

2018 ◽  
Vol 7 (9) ◽  
pp. e1476817 ◽  
Author(s):  
Florian Bochen ◽  
Benedikt Balensiefer ◽  
Sandrina Körner ◽  
Jörg Thomas Bittenbring ◽  
Frank Neumann ◽  
...  
Keyword(s):  
Vitamin D ◽  
Head And Neck Cancer ◽  
Immune Function ◽  
Head And Neck ◽  
Vitamin D Deficiency ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Prognostic Value

scholarly journals Genetically predicted serum vitamin D and COVID-19: a Mendelian randomization study

2021 ◽  
Author(s):  
Bonnie K Patchen ◽  
Andrew G Clark ◽  
Dana B Hancock ◽  
Nathan Gaddis ◽  
Patricia A Cassano
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Mendelian Randomization ◽  
Serum Vitamin ◽  
Causal Effects ◽  
European Ancestry ◽  
Vitamin D Metabolism ◽  
Serum Vitamin D ◽  
Genome Wide ◽  
Population Controls

ABSTRACTObjectivesTo investigate causality of the association of serum vitamin D with the risk and severity of COVID-19 infection.DesignTwo-sample Mendelian randomization study.SettingSummary data from genome-wide analyses in the population-based UK Biobank and SUNLIGHT Consortium, applied to meta-analyzed results of genome-wide analyses in the COVID-19 Host Genetics Initiative.Participants17,965 COVID-19 cases including 11,085 laboratory or physician confirmed cases, 7,885 hospitalized cases, and 4,336 severe respiratory cases, and 1,370,547 controls, primarily of European ancestry.ExposuresGenetically predicted variation in serum vitamin D status, based on genome-wide significant single nucleotide polymorphisms (SNPs) associated with serum vitamin D or risk of vitamin D deficiency/insufficiency.Main outcome measuresSusceptibility to and severity of COVID-19 infection, including severe respiratory infection and hospitalization.ResultsMendelian randomization analysis, powered to detect moderate effects comparable to those seen in observational studies, provided little to no evidence for an effect of genetically predicted serum vitamin D on susceptibility to or severity of COVID-19 infection. Using SNPs in loci related to vitamin D metabolism as proxies for serum vitamin D concentration, the odds ratio for a standard deviation increase in serum vitamin D was 1.04 (95% confidence interval 0.92 to 1.18) for any COVID-19 infection versus population controls, 1.05 (0.84-1.31) for hospitalized COVID-19 versus population controls, 0.96 (0.64 to 1.43) for severe respiratory COVID-19 versus population controls, 1.15 (0.99 to 1.35) for COVID-19 positive versus COVID-19 negative, and 1.44 (0.75 to 2.78) for hospitalized COVID-19 versus non-hospitalized COVID-19. Results were similar in analyses that used all SNPs with genome-wide significant associations with serum vitamin D (i.e., including SNPs in loci with no known relationship to vitamin D metabolism) and in analyses using SNPs with genome-wide significant associations with risk of vitamin D deficiency or insufficiency.ConclusionsThese findings suggest that genetically predicted differences in long-term vitamin D nutritional status do not causally affect susceptibility to and severity of COVID-19 infection, and that associations observed in previous studies may have been driven by confounding. These results do not exclude the possibility of low-magnitude causal effects, nor do they preclude potential causal effects of acute responses to therapeutic doses of vitamin D. Future directions include extension of this work to non-European ancestry populations, and high-risk populations, for example persons with comorbid disease.

Prognostic characteristics of 492 newly diagnosed breast cancer patients by serum vitamin D levels.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e12619-e12619 ◽  
Author(s):  
Luke Joseph Peppone ◽  
Mohamedtaki Abdulaziz Tejani ◽  
Karen Michelle Mustian ◽  
Michelle Christine Janelsins ◽  
Charles Stewart Kamen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Cancer Patients ◽  
Serum Vitamin ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Serum Vitamin D ◽  
Vitamin D Levels

scholarly journals Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1

Nutrients ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 4047
Author(s):  
Mustafa Sait Gönen ◽  
Merve Alaylıoğlu ◽  
Emre Durcan ◽  
Yusuf Özdemir ◽  
Serdar Şahin ◽  
...  
Keyword(s):  
Vitamin D ◽  
Clinical Outcomes ◽  
Treatment Protocol ◽  
Serum Vitamin ◽  
Serum Levels ◽  
Vitamin D Supplementation ◽  
Vitamin D Metabolism ◽  
Serum Vitamin D ◽  
Increased Risk ◽  
Vitamin D3 Supplementation

Background: We aimed to establish an acute treatment protocol to increase serum vitamin D, evaluate the effectiveness of vitamin D3 supplementation, and reveal the potential mechanisms in COVID-19. Methods: We retrospectively analyzed the data of 867 COVID-19 cases. Then, a prospective study was conducted, including 23 healthy individuals and 210 cases. A total of 163 cases had vitamin D supplementation, and 95 were followed for 14 days. Clinical outcomes, routine blood biomarkers, serum levels of vitamin D metabolism, and action mechanism-related parameters were evaluated. Results: Our treatment protocol increased the serum 25OHD levels significantly to above 30 ng/mL within two weeks. COVID-19 cases (no comorbidities, no vitamin D treatment, 25OHD <30 ng/mL) had 1.9-fold increased risk of having hospitalization longer than 8 days compared with the cases with comorbidities and vitamin D treatment. Having vitamin D treatment decreased the mortality rate by 2.14 times. The correlation analysis of specific serum biomarkers with 25OHD indicated that the vitamin D action in COVID-19 might involve regulation of INOS1, IL1B, IFNg, cathelicidin-LL37, and ICAM1. Conclusions: Vitamin D treatment shortened hospital stay and decreased mortality in COVID-19 cases, even in the existence of comorbidities. Vitamin D supplementation is effective on various target parameters; therefore, it is essential for COVID-19 treatment.

Sign in / Sign up

Export Citation Format

Share Document